Executive Summary
MBPharmaco Consulting provides strategic clinical pharmacology and model-informed drug development (MIDD) expertise to pharmaceutical and biotechnology companies across early and late-stage development.
With four decades of industry experience, we support translational decision-making through integrated PK/PD, biomarker, exposure–response, and simulation-based approaches to optimise candidate selection, dose strategy, and clinical development planning.
Our expertise spans oncology, biologics, immunology, and complex translational pharmacology, supported by high-quality regulatory documentation and submission-ready clinical pharmacology deliverables.
Our mission is to accelerate development decisions and support the timely delivery of innovative medicines to patients.
Read MoreIntegration of preclinical and clinical pharmacology to define exposure targets, evaluate exposure–response relationships, and support pharmacologically informed development strategies.
Read More
We provide model-informed clinical pharmacology strategies to support critical development decisions across discovery, translational research, early clinical development, and regulatory submission. Our expertise integrates PK/PD, biomarker modelling, exposure–response analyses, and simulation-based approaches to optimise candidate selection, dose strategy, and clinical development planning.
Read More
Development of mechanistic and population-based PK/PD models to characterise exposure, target engagement, efficacy, and safety relationships, supporting dose optimisation and translational decision-making.
Read More
Don’t hesitate to ask us questions! Fill in the form below and we will respond you shortly! We value any feedback!